INCYTE CORP (INCY) Stock Fundamental Analysis
NASDAQ:INCY - US45337C1027 - Common Stock
84.76 USD
-0.28 (-0.33%)
84.76 USD
0 (0%)
Overall INCY gets a fundamental rating of 6 out of 10. We evaluated INCY against 547 industry peers in the Biotechnology industry. INCY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INCY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes INCY very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
INCY had positive earnings in the past year.
In the past year INCY had a positive cash flow from operations.
INCY had positive earnings in 4 of the past 5 years.
INCY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
INCY has a Return On Assets of 14.96%. This is amongst the best in the industry. INCY outperforms 95.25% of its industry peers.
The Return On Equity of INCY (20.88%) is better than 95.43% of its industry peers.
The Return On Invested Capital of INCY (17.30%) is better than 96.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 16.04%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(17.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.96% | ||
| ROE | 20.88% | ||
| ROIC | 17.3% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 18.99%, INCY belongs to the best of the industry, outperforming 94.33% of the companies in the same industry.
In the last couple of years the Profit Margin of INCY has declined.
INCY has a Operating Margin of 21.69%. This is amongst the best in the industry. INCY outperforms 95.25% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
INCY's Gross Margin of 93.41% is amongst the best of the industry. INCY outperforms 93.60% of its industry peers.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.69% | ||
| PM (TTM) | 18.99% | ||
| GM | 93.41% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so INCY is still creating some value.
INCY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for INCY has been reduced compared to 5 years ago.
Compared to 1 year ago, INCY has a worse debt to assets ratio.
2.2 Solvency
INCY has an Altman-Z score of 7.75. This indicates that INCY is financially healthy and has little risk of bankruptcy at the moment.
INCY has a better Altman-Z score (7.75) than 82.27% of its industry peers.
INCY has a debt to FCF ratio of 0.04. This is a very positive value and a sign of high solvency as it would only need 0.04 years to pay back of all of its debts.
INCY has a better Debt to FCF ratio (0.04) than 96.89% of its industry peers.
INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 44.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.04 | ||
| Altman-Z | 7.75 |
ROIC/WACC1.78
WACC9.72%
2.3 Liquidity
INCY has a Current Ratio of 2.85. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY's Current ratio of 2.85 is on the low side compared to the rest of the industry. INCY is outperformed by 66.18% of its industry peers.
A Quick Ratio of 2.78 indicates that INCY has no problem at all paying its short term obligations.
INCY has a worse Quick ratio (2.78) than 64.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 433.67% over the past year.
Measured over the past years, INCY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.21% on average per year.
INCY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.88%.
Measured over the past years, INCY shows a quite strong growth in Revenue. The Revenue has been growing by 14.46% on average per year.
EPS 1Y (TTM)433.67%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%186.26%
Revenue 1Y (TTM)18.88%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%16.46%
3.2 Future
The Earnings Per Share is expected to grow by 23.02% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -0.47% on average over the next years.
EPS Next Y379.32%
EPS Next 2Y137.87%
EPS Next 3Y90.13%
EPS Next 5Y23.02%
Revenue Next Year14.97%
Revenue Next 2Y13%
Revenue Next 3Y11.84%
Revenue Next 5Y-0.47%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.21, INCY is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 95.25% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.24, INCY is valued a bit cheaper.
The Price/Forward Earnings ratio is 11.35, which indicates a very decent valuation of INCY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 96.89% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.81. INCY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.21 | ||
| Fwd PE | 11.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaply inside the industry as 95.43% of the companies are valued more expensively.
INCY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INCY is cheaper than 95.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.28 | ||
| EV/EBITDA | 12.25 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
INCY's earnings are expected to grow with 90.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y137.87%
EPS Next 3Y90.13%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
84.76
-0.28 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.56%
Inst Owner Change4.58%
Ins Owners2%
Ins Owner Change5.72%
Market Cap16.55B
Analysts75.88
Price Target84 (-0.9%)
Short Float %3.92%
Short Ratio4.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.72%
Max EPS beat(2)11.9%
EPS beat(4)2
Avg EPS beat(4)1.1%
Min EPS beat(4)-10.01%
Max EPS beat(4)11.9%
EPS beat(8)3
Avg EPS beat(8)-5.09%
EPS beat(12)5
Avg EPS beat(12)-7.34%
EPS beat(16)7
Avg EPS beat(16)-6.93%
Revenue beat(2)2
Avg Revenue beat(2)3.69%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.94%
Revenue beat(4)4
Avg Revenue beat(4)3%
Min Revenue beat(4)1.09%
Max Revenue beat(4)3.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.67%
Revenue beat(16)9
Avg Revenue beat(16)0.51%
PT rev (1m)7.76%
PT rev (3m)11.2%
EPS NQ rev (1m)6.34%
EPS NQ rev (3m)4.33%
EPS NY rev (1m)7.02%
EPS NY rev (3m)6.83%
Revenue NQ rev (1m)2.74%
Revenue NQ rev (3m)2.57%
Revenue NY rev (1m)2.45%
Revenue NY rev (3m)2.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.21 | ||
| Fwd PE | 11.35 | ||
| P/S | 3.61 | ||
| P/FCF | 17.28 | ||
| P/OCF | 16.5 | ||
| P/B | 3.97 | ||
| P/tB | 4.26 | ||
| EV/EBITDA | 12.25 |
EPS(TTM)5.23
EY6.17%
EPS(NY)7.47
Fwd EY8.81%
FCF(TTM)4.91
FCFY5.79%
OCF(TTM)5.14
OCFY6.06%
SpS23.48
BVpS21.36
TBVpS19.91
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.96% | ||
| ROE | 20.88% | ||
| ROCE | 21.89% | ||
| ROIC | 17.3% | ||
| ROICexc | 47.5% | ||
| ROICexgc | 57.26% | ||
| OM | 21.69% | ||
| PM (TTM) | 18.99% | ||
| GM | 93.41% | ||
| FCFM | 20.9% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexcg growth 3Y-34.92%
ROICexcg growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.04 | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 49.5% | ||
| Cap/Sales | 0.98% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.43% | ||
| Profit Quality | 110.01% | ||
| Current Ratio | 2.85 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 7.75 |
F-Score6
WACC9.72%
ROIC/WACC1.78
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)433.67%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%186.26%
EPS Next Y379.32%
EPS Next 2Y137.87%
EPS Next 3Y90.13%
EPS Next 5Y23.02%
Revenue 1Y (TTM)18.88%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%16.46%
Revenue Next Year14.97%
Revenue Next 2Y13%
Revenue Next 3Y11.84%
Revenue Next 5Y-0.47%
EBIT growth 1Y1425.09%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year330.79%
EBIT Next 3Y84.53%
EBIT Next 5Y24.25%
FCF growth 1Y34.45%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y28.43%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%